This trial is evaluating whether Pembrolizumab will improve 1 primary outcome, 3 secondary outcomes, and 1 other outcome in patients with Pelvic Neoplasms. Measurement will happen over the course of Up to 28 days.
This trial requires 25 total participants across 1 different treatment group
This trial involves a single treatment. Pembrolizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"In the UK, approximately two thirds of all women (66%) have pelvic cancer which can vary in their subtype. It is the most common form of cancer in those diagnosed with pelvic (16%), perineal (12%) and anal (8%) lesions. Diagnosis of pelvic tumours can be difficult as physical symptoms are less frequent than in other organs. Surgery is the main treatment. Prophylactic treatment can reduce the amount of people who develop invasive cancers in the future." - Anonymous Online Contributor
"For most patients, radical surgery with pelvic lymphadenectomy is their most common treatment mode. The surgical decision is dependent on many clinician and patient factors. If patients are diagnosed with a high-risk disease before they undergo surgery, they may require an extended adjuvant or neoadjuvant chemotherapy after surgery." - Anonymous Online Contributor
"The absence of lower abdominal pain, pelvic mass and an ileocecal valve in a woman older than 60 years is highly suggestive of an adenocarcinoma of the endometrium, and a pelvic mass or adenocarcinoma in an elderly person without these findings suggests a non-endometrial malignancy. Other pelvic neoplasms also require imaging investigations." - Anonymous Online Contributor
"Pelvic neoplasms can be caused by trauma, infection, embryonal cell tumors, sarcoma, malignant melanoma, and adenocarcinoma"
"Neural cell adhesion molecule\n\nNeural cell adhesion molecule, also known as NCAM, is a multi-domain glycoprotein present on the surface of neurons and some other neuron-like cells, such as glia, that regulate axonal growth and guidance." - Anonymous Online Contributor
"The current research confirms that the incidence of neoplasms that can be cured is low. However, it does not rule out that there may be a small proportion of patients who might be able to have an enduring disease-free remission, and that further research is necessary to understand how best to treat pelvic neoplasms." - Anonymous Online Contributor
"Around 20% of US men and 3.1% of US women develop uterine, serous, endometrioid, clear-cell carcinomatous, mucinous, or transitional cell carcinoma of the bladder a year. These cases have a mean age around 68.5 yr. More men and women were diagnosed with squamous cell carcinoma of the lung or with malignant mesothelioma around ages of 80 yr and older. There were more men than women for most urinary malignancies around aging years 70–79 yr." - Anonymous Online Contributor
"There was limited information on the use of PD-1 therapy as a monotherapy or in combination with non-PD-1 agents. There was only one other study that focused on PD-1 monotherapy and was only conducted with patients newly diagnosed with metastatic melanomas." - Anonymous Online Contributor
"This analysis showed that the patients who were eligible had similar DSS than those with other eligibility requirements. Overall, the patients' baseline disease characteristics as well as age, BMI, and performance status were important in the prognosis." - Anonymous Online Contributor
"The incidence of most types of neoplasms is very low in individuals with a diagnosis of Ewing's sarcoma. The current treatment for Ewing's sarcoma consists of amputation, chemotherapy, and radiation, with a very low chance of obtaining a cure. The Ewing's sarcoma incidence rate is estimated to be two per 1,000,000 live births. The risk of developing pelvic neoplasms is estimated to be about 0.06–0.3% per year for males and about 0.1 for females. Thus the risk of developing pelvic neoplasms is 0.05–0.2% per year for both genders, and the risk is lower if men exceed 50 years of age." - Anonymous Online Contributor
"In a recent study, findings suggest that pembrolizumab can be an effective monotherapy in treatment-naive patients with pelvic cancer and that the drug increases QOL for these patients." - Anonymous Online Contributor
"Pembrolizumab is a well-tolerated drug which could be used even in the absence of PD-L1 expression using this drug combination. However, the small sample size and the short follow-up time could limit the impact of other potential side effects." - Anonymous Online Contributor